

Tanin Intragumtornchai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8467704/publications.pdf>

Version: 2024-02-01

33
papers

373
citations

1039880

9
h-index

794469

19
g-index

33
all docs

33
docs citations

33
times ranked

550
citing authors

#	ARTICLE	IF	CITATIONS
1	A Predictive Model for Life-Threatening Neutropenia and Febrile Neutropenia after the First Course of CHOP Chemotherapy in Patients with Aggressive Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 2000, 37, 351-360.	0.6	80
2	Updated 6 Year Follow-Up Of The PRIMA Study Confirms The Benefit Of 2-Year Rituximab Maintenance In Follicular Lymphoma Patients Responding To Frontline Immunochemotherapy. <i>Blood</i> , 2013, 122, 509-509.	0.6	66
3	Myelodysplastic syndromes in Thailand: a retrospective pathologic and clinical analysis of 117 cases. <i>Leukemia Research</i> , 1998, 22, 453-460.	0.4	46
4	Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.. <i>Blood</i> , 2009, 114, 920-920.	0.6	38
5	Non-Hodgkin's lymphomas in Thailand: A retrospective pathologic and clinical analysis of 1391 cases. <i>Cancer</i> , 1996, 78, 1813-1819.	2.0	31
6	Non-Hodgkin lymphoma in South East Asia: An analysis of the histopathology, clinical features, and survival from Thailand. <i>Hematological Oncology</i> , 2018, 36, 28-36.	0.8	23
7	Event free survival at 24 months is a strong surrogate prognostic endpoint of peripheral T cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 578-585.	0.8	13
8	Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's lymphoma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1306-1314.	0.6	11
9	Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessibility. <i>Leukemia and Lymphoma</i> , 2013, 54, 83-89.	0.6	10
10	Clinical Characteristics and Outcomes of Limited-Stage Primary Extranodal Versus Nodal Diffuse Large B-Cell Lymphoma (DLBCL) in Thailand: A Nationwide Multi-Institutional Registry of 920 Cases in Thailand. <i>Blood</i> , 2015, 126, 2676-2676.	0.6	8
11	Treatment of Myelodysplastic Syndrome With Low-Dose Human Granulocyte Colony-Stimulating Factor: A Multicenter Study. <i>International Journal of Hematology</i> , 2001, 74, 144-146.	0.7	7
12	Characteristics, treatment patterns, prognostic determinants and outcome of peripheral T cell lymphoma and natural killer/T cell non-Hodgkin Lymphoma in older patients: The result of the nationwide multi-institutional registry Thai Lymphoma Study Group. <i>Journal of Geriatric Oncology</i> , 2020, 11, 62-68.	0.5	6
13	Hyperfibrinolysis and the risk of hemorrhage in stable cirrhotic patients. <i>Asian Biomedicine</i> , 2010, 4, 199-206.	0.2	6
14	<sc>S</sc>tatin use is safe and does not impact prognosis in patient with de novo follicular lymphoma treated with immunochemotherapy: <sc>A</sc>n exploratory analysis of the PRIMA cohort study. <i>American Journal of Hematology</i> , 2016, 91, 410-415.	2.0	5
15	Estrogen receptor beta expression and prognosis of diffuse large B cell lymphoma. <i>Hematology</i> , 2018, 23, 235-241.	0.7	5
16	Secondary central nervous system relapse in diffuse large B cell lymphoma in a resource limited country: result from the Thailand nationwide multi-institutional registry. <i>Annals of Hematology</i> , 2017, 96, 57-64.	0.8	4
17	Alemtuzumab in Combination with CHOP and ESHAP as First-Line Treatment in Peripheral T-Cell Lymphoma.. <i>Blood</i> , 2006, 108, 4740-4740.	0.6	4
18	A Nationwide Prospective Multicenter Study of Clinical Features and Outcomes of Non-Hodgkin Lymphoma in Thailand: An Analysis of 939 Cases. <i>Blood</i> , 2011, 118, 2064-2064.	0.6	4

#	ARTICLE	IF	CITATIONS
19	Updated Results of the PRIMA Study Confirms the Benefit of 2-Years Rituximab Maintenance In Follicular Lymphoma Patients Responding to Immunochemotherapy.. Blood, 2010, 116, 1788-1788.	0.6	3
20	Event-free survival at 12 months is a strong surrogate endpoint for stage 1 diffuse large B cell lymphoma: a report from Nation Wide Registry Thai Lymphoma Study Group. Leukemia and Lymphoma, 2020, 61, 2614-2621.	0.6	1
21	Clinical Features and Treatment Outcomes of Angioimmunoblastic T-Cell Lymphoma: An Analysis from a Nationwide Multicenter Registry, Thailand. Blood, 2015, 126, 5064-5064.	0.6	1
22	Extranodal NK/T-cell lymphoma: basic questions remain. Oncology, 2010, 24, 359, 362.	0.4	1
23	Infectious Complications in Asian Patients Treated with Alemtuzumab: Results From a Multicenter Study.. Blood, 2009, 114, 5009-5009.	0.6	0
24	Diet, Lifestyle and Venous Thromboembolism (VTE) in Thai Population.. Blood, 2009, 114, 1414-1414.	0.6	0
25	Protein C and Protein S Levels Are Correlated with Bleeding Symptoms In Thai Population.. Blood, 2010, 116, 3804-3804.	0.6	0
26	Mantle Cell Lymphoma, Rare Lymphoma Entity: A Result of Lymphoma Registry in Thailand. Blood, 2015, 126, 3326-3326.	0.6	0
27	Consolidation Radiotherapy Improved Survival in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry of 816 Cases in Thailand. Blood, 2015, 126, 2712-2712.	0.6	0
28	Stage Adjusted International Prognostic Index (St-IPI) Is a Simple and Better Prognostic Model in Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL): A Nationwide Multi-Institutional Registry in Thailand. Blood, 2015, 126, 5030-5030.	0.6	0
29	Treating Hodgkin Lymphoma without Dacarbazine: A Lesson Learned from Thailand. Blood, 2015, 126, 5002-5002.	0.6	0
30	Validation of German High-Grade Non-Hodgkin's Lymphoma (DSHNHL) Prognostic Model and the Impact of Treatment on Secondary Central Nervous System (CNS) Relapse in Diffuse Large B-Cell Lymphoma (DLBCL) in a Developing Country: Report from the Nationwide Multi-Institutional Registry of Thai Lymphoma Study Group (TLSG). Blood, 2015, 126, 1471-1471.	0.6	0
31	Clinical Features, Outcomes and Prognosis of Oropharyngeal Lymphoma: An Analysis from the Thai Lymphoma Study Group (TLSG). Blood, 2015, 126, 5088-5088.	0.6	0
32	EFS12 Is a Powerful Predictive Tool for Outcomes in Stage I Aggressive Non Hodgkin Lymphoma: A Report from Nationwide Registry in a Resource Limited Country Thai Lymphoma Study Group. Blood, 2019, 134, 2128-2128.	0.6	0
33	Mantle cell lymphoma in Thai patients. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 2004, 87, 1071-5.	0.4	0